llama-derived nanobodies to the exosite of activated protein C (coagulant therapeutics)

N/A

Report date: 2025/03/20 15:41:31

Base Information

Drug Namellama-derived nanobodies to the exosite of activated protein C (coagulant therapeutics)

Drug Alias Namevitamin K dependent protein C inhibitor (coagulant therapeutics)

ClassificationBiologics > Protein drugs > Recombinant proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionVitamin K-dependent protein C inhibitors

TargetsVitamin K-dependent protein C

Therapy Area/IndicationsWounds and InjuriesHemophilia A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCoagulant Therapeutics Corp

China Registration ClassN/A

Develop Information

Active CompaniesCoagulant Therapeutics Corp

Inactive CompaniesN/A

Active IndicationsWounds and InjuriesHemophilia A

Inactive IndicationsN/A

Other Information

ATC CodeN/A